CNBC World News

Benedetto Vigna said that despite limited supply, the company continues to expand its reach among younger, new clients.

Novavax's vaccine and new shots from Pfizer and Moderna are expected to roll out in the U.S. within weeks, pending potential approvals from the FDA.

These days, only 12% of Americans consider themselves wealthy, including just 29% of millionaires. Some go so far as to say they’re poor.

Chinese tech company Baidu reported better-than-expected revenue, up by 15% year-on-year in the second quarter.

Meta's Twitter clone called Threads is now available on the web for people to access via their desktop computers.

Cryptocurrency exchange Coinbase is taking a stake in Circle, the issuer of the USDC stablecoin.

Thailand has been administered by a caretaker government since March, with its parliament in deadlock.

One analyst is of the view that only nuclear power can deliver cost effective, reliable, and clean energy, solving the problem of reliability

Xpeng is attempting to revive its business this year, after its share price sank by more than 80% in 2022

Despite rising yields, tech rallied. Investors are anticipating Nvidia’s earnings report — if it meets its revenue forecast, expect its stock to surge.

As working age populations decline, Krishna said AI presents one of the only solutions to addressing potential productivity shortfalls.

A confluence of factors is stoking fears that shortage of rice supplies could mark a return to a broad increase in the prices of other food commodities in Asia.

India has slapped a 40% export tax on onions on the back of higher domestic prices of the vegetable.

These are the behaviors that appear to lead to a happy and well-lived life, based on the study’s findings.

Arm is aiming to sell shares to the public during a historically slow period for U.S. tech IPOs.

It's the latest resolution in a string of cases related to price-fixing, referring to competitors banding together to artificially set the price of a product. 

Pfizer hopes that its respiratory syncytial virus vaccine will be available to the public by the end of October or the beginning of November.

A string of executive changes over the last few months come as the company faces more pressure than ever — and executives want to try something new.

Arm, which is owned by SoftBank, is expected to file for its initial public offering as soon as Monday, according to reports.

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.